Abatacept in the Treatment of Uveitis

Oregon Health & Science University (OHSU) logo

Oregon Health & Science University (OHSU)

Status and phase

Completed
Phase 2

Conditions

Uveitis

Treatments

Drug: Abatacept

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01279954
e7035

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of abatacept in the treatment of uveitis.

Enrollment

10 patients

Sex

All

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with vision-threatening autoimmune uveitis
  • failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion criteria

serious concomitant illness that could interfere with the subject's participation

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

10 participants in 2 patient groups

open-label abatacept first, then 5 mg/kg abatacept
Experimental group
Description:
10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)
Treatment:
Drug: Abatacept
open-label abatacept first, then 10 mg/kg abatacept
Experimental group
Description:
10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)
Treatment:
Drug: Abatacept

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems